Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* has type 2 diabetes and is at least 18 years of age and no older than 78 years of age~* is male or is a female who is unlikely to conceive children~* is on stable doses of a peroxisome proliferator-activated receptor gamma agonist and metformin OR metformin and a sulfonylurea agent~Exclusion Criteria:~* has type 1 diabetes~* has taken a dipeptidyl peptidase (DPP-4) inhibitor or a glucagon-like peptide-1 (GLP-1) analogue~* is on a weight loss program that is not in the maintenance phase or has started a weight loss medication within 8 weeks of screening~* has had surgery within 30 days of screening or has major surgery planned during the study~* is on or is likely to require treatment with corticosteroids for more than 2 weeks~* has a history of active liver disease, including hepatitis B or C, cirrhosis, or gallbladder disease~* is human immunodeficiency virus (HIV) positive~* has congestive heart failure, or has had new or worsening symptoms of coronary heart disease within 3 months prior to screening~* has had acute coronary syndrome, coronary artery intervention, or stroke within 3 months of screening~* has severe active peripheral vascular disease~* has a history of cancer or blood disorder~* is pregnant or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): Sitagliptin 100 mg tablet orally once daily for 26 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to sitagliptin orally once daily for 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).